Clinical trials: Advanced Cancers of the Prostate
Advanced Prostate Cancer, Metastatic Prostate Cancer
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
The main aim of this study is to assess the effectiveness and safety of the 6-month formulation of triptorelin pamoate in Chinese participants with locally advanced or metastatic cancer of the prostate.
- Conditions
- Advanced Prostate Cancer, Metastatic Prostate Cancer, Locally Advanced Prostate Cancer
- Trial name
- NCT05590793
- Testing
- Triptorelin pamoate (embonate) salt
- Where
- 36 sites in China
- Volunteers
- 195 people
- Sponsor
- Ipsen
Stage III Prostate Cancer
Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer
This phase I trial is studying the best way to give omega-3 fatty acids in treating patients with advanced prostate cancer. Omega-3 fatty acids may slow disease progression and may be an effective treatment for patients with…
- Trial name
- NCT00996749
- Testing
- omega-3 fatty acid, bone scan, dual x-ray absorptometry
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using triptorelin may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003026
- Testing
- bicalutamide, flutamide, triptorelin
- Where
- 17 sites in Belgium, Israel and 5 more
- Volunteers
- 966 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
This phase I/II trial studies the side effects of avelumab when given in different combinations with utomilumab, anti-OX40 antibody PF-04518600, and radiation therapy in treating patients with malignancies that have spread to…
- Conditions
- Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03217747
- Testing
- Avelumab, Ivuxolimab, Radiation Therapy
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- M.D. Anderson Cancer Center
Cholangiocarcinoma, Chondrosarcoma
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors…
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Trial name
- NCT04521686
- Testing
- LY3410738, Gemcitabine, Cisplatin
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body.
- Conditions
- Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
- Trial name
- NCT07005154
- Testing
- ASP5541, Prednisone, Prednisolone
- Where
- 54 sites in United States, China and 10 more
- Volunteers
- 218 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Cancer, Solid Tumor
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.
- Trial name
- NCT00333502
- Testing
- Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- NewLink Genetics Corporation
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02001623
- Testing
- Tisotumab Vedotin (HuMax-TF-ADC)
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 195 people
- Sponsor
- Seagen Inc.
Prostate Cancer
FACBC Outcomes for Post Prostatectomy
Investigators will perform a study with 162 patients in whom there is a strong suspicion of prostate cancer that has returned to the body after having a prostatectomy.
- Trial name
- NCT01666808
- Testing
- FACBC, Radiation therapy
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Emory University
Prostate Cancer Recurrent
The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer
In order to elucidate if FSH can have testosterone like effects, samples from young, non-smoking healthy volunteers, with normal body mass index, and with pharmacologically induced gonadotropin deficiency will be studied…
- Trial name
- NCT04134130
- Testing
- Degarelix 120 MG [Firmagon], Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector, Testosterone Undecanoate
- Where
- Sweden
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Lund University
Prostate Cancer
SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00026377
- Testing
- bicalutamide, flutamide, goserelin acetate
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago
Advanced Prostate Adenocarcinoma
To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer
To determine an effective dose of VERU-100 for the treatment of advanced prostate cancer by assessing its effect on testosterone levels by Day 28 and maintenance through Day 91.
- Trial name
- VERU-100 (NCT04843319)
- Testing
- VERU-100
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Veru Inc.
Prostate Cancer
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
The purpose of this study is to determine if asymptomatic or minimally symptomatic patients with metastatic prostate cancer who have not received chemotherapy live longer when treated with ipilimumab than those treated with a…
- Trial name
- NCT01057810
- Testing
- Ipilimumab
- Where
- 134 sites in United States, Argentina and 22 more
- Volunteers
- 837 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer (Adenocarcinoma)
Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
This study will assess the effects and safety of deutenzalutamide combined with hormone therapy before and after prostate cancer surgery, with docetaxel chemotherapy added before surgery.
- Trial name
- NCT07907653
- Testing
- Deutenzalutamide, Docetaxel, ADT
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Prostate Cancer
Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients
The present study will provide information on whether the somatostatin analog, octreotide acetate, could have an inhibitory effect on circulating chromogranin A.
- Trial name
- NCT00166725
- Testing
- Octreotide LAR
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Novartis
Prostate Cancer
Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer
The purpose of this study is to determine if the drug dutasteride increases expression of genes that slow the growth of prostate cancer during treatment with intermittent androgen ablation therapy (hormone therapy).
- Trial name
- NCT00668642
- Testing
- Dutasteride
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Health
Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC)
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in…
- Conditions
- Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT03811652
- Testing
- MEDI7247
- Where
- 3 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- MedImmune LLC
mCRPC or Advanced/Metastatic Solid Tumors
A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3902 in patients with mCRPC and other advanced solid tumours.
- Trial name
- NCT07533708
- Testing
- HLX3902
- Where
- 5 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai Henlius Biotech
Ovarian Neoplasms, Breast Neoplasms
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
To determine the safety and immunogenicity profile of two (2) different doses of the vaccine DPX-0907 to treat breast, ovarian and prostate cancer.
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Trial name
- NCT01095848
- Testing
- DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Advanced Cancers of the Prostate, Cancers of the Lung
Multilevel Intervention for Precision Oncology
The investigators are rolling out a 3 level intervention designed to improve the use of Precision Oncology at 8 VA medical centers.
- Trial name
- MIPO (NCT06825715)
- Testing
- Multilevel intervention
- Where
- United States
- Volunteers
- 2,653 people
- Sponsor
- VA Office of Research and Development